Stockreport

Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment [Yahoo! Finance]

NLS Pharmaceutics Ltd. - Ordinary Shares  (NLSP) 
PDF ZURICH and NESS ZIONA, Israel Feb. 25, 2025 /PRNewswire/ -- NLS Pharmaceutics Ltd . (Nasdaq: NLSP) ("NLS") and Kadimastem Ltd . (TASE: KDST) ("Kadimastem"), a clinical- [Read more]